z-logo
Premium
IMMUNOTHERAPY OF CANCER WITH CELL WALL SKELETON OF MYCOBACTERIUM BOVIS ‐BACILLUS CALMETTE‐GUÉRIN: EXPERIMENTAL AND CLINICAL RESULTS
Author(s) -
Yamamura Yuichi,
Azuma Ichiro,
Taniyama Tadayoshi,
Sugimura Kazuhisa,
Hirao Fumio,
Tokuzen Reiko,
Okabe Midori,
Nakahara Waro,
Yasumoto Kousei,
Ohta Mitsuo
Publication year - 1976
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1976.tb41699.x
Subject(s) - medicine , family medicine , medical school , cancer , medical education
Adjuvant and antitumor activities of CWS prepared from cells of mycobacteria, nocardia, and corynebacteria were examined. Oil-attached CWS of M. bovis BCG (BCG-CWS) stimulated the generation of cell-mediated cytotoxic effector cells in mice. Tumor growth was suppressed in mice inoculated intradermally with a mixture of oil-attached CWS and living tumor cells. Systemic and specific tumor immunity was demonstrated in mice in which tumor growth was suppressed. Tumor growth was also suppressed by oil-attached CWS of BCG or N. rubra in autochthonous autografts of spontaneous mammary adenocarcinoma and methylcholanthrene-induced fibrosarcoma in mice. The intravenous injection of oil-attached BCG-CWS prevents the appearance of lung cancer in rabbits by the instillation of chemical carcinogens. It was also shown that treatment with oil-attached BCG-CWS was able to elevate the immunologically depressed state of tumor-bearing mice to a normal level, as determined by a cell-mediated cytotoxicity assay that empolyed chromium release as the standard. Preliminary results suggest that oil-attached BCG-CWS is useful as an immunotherapeutic agent for both lung cancer and for malignant melanoma, leukemia, Hodgkin's disease, and other neoplastic diseases and that this agent operates without any significant complications.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here